RxDoctor Payments Data

Mikael Fadoul, MD

Vascular Surgery · Newark, DENPI 1053974824

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,137 of the $7,043 with a category attached, or 87.1%. It is spread thinly across 14 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations.

$7,043in general payments, 2019–2025

Across 133 payments — averaging $52.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$1K
  • W. L. Gore & Associates, Inc.$1K
  • Inari Medical, Inc.$1K
  • Boston Scientific$812
  • Silk Road Medical, Inc.$805
  • Endologix LLC$475
  • plus $1K from 8 others

What the payments were for

  • Travel & lodging$90713%
  • Food & beverage$6,13787%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,299
Medicare patients
69
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate20$166

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →